911826-39-6

Basic information

• Product Name: trans-4-(2-chloro-5-nitropyrimidin-4-ylamino)cyclohexanol
• Synonyms: trans-4-(2-chloro-5-nitropyrimidin-4-ylamino)cyclohexanol
• CAS NO: 911826-39-6
• Molecular Weight: 272.691
• Mol File: 911826-39-6.mol

Chemical Properties

• CAS DataBase Reference: trans-4-(2-chloro-5-nitropyrimidin-4-ylamino)cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-(2-chloro-5-nitropyrimidin-4-ylamino)cyclohexanol(911826-39-6)
• EPA Substance Registry System: trans-4-(2-chloro-5-nitropyrimidin-4-ylamino)cyclohexanol(911826-39-6)

Safety Data

• Hazardous Substances Data: 911826-39-6(Hazardous Substances Data)

Upstream product

• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 49845-33-2 2,4-Dichloro-5-nitropyrimidine 

Downstream Products

• 911826-40-9 trans-4-(2-(1H-benzo[d]imidazol-1-yl)-5-nitropyrimidin-4-ylamino)cyclohexanol 

Relevant articles and documents

Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors

In present study, we described the synthesis and biological evaluation of a new class of EGFR inhibitors containing 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine scaffold. Thirty-one compounds were synthesized. Among them, compound C9 displayed the IC50 of 29.4 nM against HCC827 cell line and 1.9 nM against EGFRL858R. Compound C12 showed moderate inhibitory activity against EGFRL858R/T790M/C797S (IC50 = 114 nM). Western bolt assay suggested that compound C9 significantly inhibited EGFR phosphorylation. In vivo test, compound C9 remarkably exhibited inhibitory effect on tumor growth at 5.0 mg/kg by oral administration in established nude mouse HCC827 xenograft model. These results indicate that the 2,9-disubstituted 8-phenylsulfinyl/phenylsulfinyl-9H-purine derivatives can act as potent EGFR(L858R) inhibitors and effective anticancer agents. Additionally, optimization of compound C12 may result in discovering the fourth-generation EGFR-TKIs.

PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).